DOK7 and myopathy: As mentioned, we previously demonstrated that DOK7 gene therapy activates muscle‐specific kinase MuSK to enlarge NMJs, and ameliorates myopathies characterized by NMJ defects in mouse models irrespective of the presence or absence of a dok‐7 gene mutation, attesting to its potential in a range of neuromuscular diseases (Arimura et al, 2014).